2-Fluorodeschloroketamine for the treatment of depression, including treatment-resistant depression

Abstract

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the present invention demonstrates that administration of 2-fluorodeschloroketamine (2-FDCK) is effective for treating depression, particularly for treating treatment-resistant depression.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 256,728, entitled "2-Fluorodeschloroketamine for the Treatment of Depression, Including Treatment-Resistant Depression," filed October 18, 2021. This application also claims priority and the benefit under 35 U.S.C. 365(c) to U.S. patent application Ser. No. 13 / 837,539, filed March 15, 2013. The disclosures of each of the above applications are incorporated herein by reference in their entirety. Technical Field The present invention relates to methods and compositions for treating depression. More particularly, the present invention relates to the administration of 2-fluorodeschloroketamine (2-FDCK) to treat treatment-refractory or treatment-resistant depression. [Background technology]

[0002] Depression, or major depressive disorder (MDD), is one of the most disabling of all medical disorders, with a lifetime prevalence of approximately 17% (Kessler et al., Arch Gen Psychiatry. 62(6):593-602 (2005)). It frequently presents early in life, has a chronic course, and can adversely affect the prognosis of other medical illnesses, such as coronary vascular disease, diabetes, and osteoporosis.

[0003] Depression is characterized by a depressed mood and a marked decrease in interest or pleasure in activities. Other symptoms include significant weight loss or weight gain, decreased or increased appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, decreased ability to think or concentrate or indecisiveness, recurrent thoughts of death, suicidal ideation, or suicide attempts. A variety of physical symptoms may also be present. Depressed mood is common, especially after experiencing setbacks in life, but a depressive disorder is only diagnosed when symptoms reach a threshold and last for at least two weeks. The severity of depression can range from mild to very severe. In most cases, it is transient, but it can recur or become chronic. Some people only have one episode and fully return to pre-morbid functioning. However, more than 50 percent of people who initially suffer from one major depressive episode will eventually develop another.

[0004] Depression is more prevalent in women than in men. The prevalence of unipolar depressive episodes is estimated at 1.9% in men and 3.2% in women, with 5.8% of men and 9.5% of women experiencing a depressive episode within a 12-month period. These prevalence figures vary across populations and may be higher in some populations. A World Health Organization study reported that depression is the leading cause of living with disability worldwide and the fourth leading cause of disability-adjusted life years. Disability-adjusted life years is a measure of the loss of an individual's productive life span and takes into account premature mortality (Murray et al., Lancet. 349(9063):1436-1442 (1997)).

[0005] The treatment of depression was revolutionized nearly half a century ago with the serendipitous discovery of monoamine oxidase inhibitors and tricyclic antidepressants. Since then, the availability of numerous new drugs with better side-effect profiles has greatly improved our ability to safely treat a significant proportion of patients. However, the new drugs are primarily drugs that merely augment or potentiate the effects of existing drugs by exerting their primary biochemical effect by increasing monoamine levels within the synapse.

[0006] Unfortunately, current depression medications take weeks to months to become fully effective, during which time patients continue to suffer from symptoms and continue to be at risk for self-harm and damage to their personal and professional lives. Indeed, the several-week delay in the onset of action of conventional antidepressants is recognized as a major limitation, resulting in considerable morbidity and a high risk of suicidal behavior, especially during the first 9 days of starting an antidepressant (Jick et al., Jama. 292(3):338-343 (2004)). Thus, pharmacological strategies that provide rapid onset and sustained antidepressant effects within hours or days would have a tremendous impact on public health. Although patients with major depression respond to antidepressant treatment, some patients do not improve after two consecutive courses of standard antidepressants and are considered to have the so-called “treatment-resistant depression” (TRD).

[0007] TRD represents a heterogeneous condition, likely with multiple causal mechanisms. Patients with TRD exhibit diverse symptoms, courses, histories, and comorbid conditions similar to those of treatment-responsive MDD. However, little is known about what distinguishes treatment-responsive from non-responsive patients. The extent to which the etiology or pathophysiology of patients with TRD differs from that of patients with treatment-responsive MDD remains largely unknown, although several reports suggest that a history of childhood stress increases treatment resistance (Bernet et al., Depress Anxiety. 9(4):169-74 (1999); Nanni et al., Am J Psychiatry. 169(2):141-51 (2012); Williams et al., Transl Psychiatry. 3; 6():e799 (2016)), and patients with TRD exhibit differences in brain circuit function (Dunlop et al., Am J Psychiatry. 174(6):533-545 (2017)). Nevertheless, its pathogenesis remains unclear.

[0008] Ketamine (a racemic mixture of the corresponding S- and R-enantiomers) is an N-methyl-D-aspartate (NMDA) receptor antagonist with a wide range of effects in humans, including analgesia, anesthesia, hallucinations, dissociative effects, and blood pressure and bronchodilation. Ketamine is primarily used for the induction and maintenance of general anesthesia. Other uses include sedation in intensive care, analgesia (especially in critical care), and treatment of bronchospasm. Ketamine has also been shown to be effective in treating depression, especially in patients who have failed other antidepressant treatments. In patients with major depressive disorder, ketamine has additionally been shown to provide a rapid antidepressant effect that acts within 2 hours. In 2019, the U.S. Food and Drug Administration approved Spravato® (esketamine, S-ketamine, the "S" enantiomer of ketamine) nasal spray in combination with an oral antidepressant for the treatment of depression in adults (TRD) who have tried other antidepressants without success. S-ketamine enantiomers may allow for lower dosages due to their greater potency or affinity for NMDA receptors. However, due to the risk of serious adverse events due to sedation and dissociation with Spravato administration, and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system in the United States under a risk evaluation and mitigation strategy (REMS). Spravato is self-administered by patients under the supervision of a medical professional in a certified treatment center. Summary of the Invention [Problem to be solved by the invention]

[0009] There remains a need to provide effective treatments for patients with depression, particularly those with treatment-resistant or refractory depression. [Means for solving the problem]

[0010] The inventors of the present invention have surprisingly discovered that 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one (2-FDCK) has an unexpectedly flatter dose-response curve compared to S-ketamine in treating patients with depression, which may lead to reduced side effects, particularly for patients with TRD. As a result, treatment of depression with 2-FDCK may allow patients to self-administer, and ultimately 2-FDCK may be sold over the counter (through retail stores) at low cost to patients as a prescription drug.

[0011] Disclosure Summary One embodiment of the present invention provides a method for treating treatment-refractory or treatment-resistant depression, comprising administering to a patient in need thereof a therapeutically effective amount of 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one (2-FDCK).

[0012] In another aspect, the present disclosure provides a method for treating treatment-refractory or treatment-resistant depression, comprising administering to a patient in need thereof a therapeutically effective amount of 2-FDCK in combination with at least one antidepressant, together with a pharma- ceutically acceptable carrier.

[0013] In some embodiments, 2-FDCK is administered in an amount ranging from about 0.01 mg / kg to about 1.5 mg / kg. In other embodiments, 2-FDCK is administered in an amount ranging from about 0.2 mg / kg to about 0.5 mg / kg. In yet other embodiments, 2-FDCK is administered in an amount ranging from about 0.01 mg to about 1000 mg. In further embodiments, 2-FDCK is administered in an amount ranging from about 1 mg to about 100 mg.

[0014] In some embodiments, the 2-FDCK forms part of a composition, which further comprises at least one pharma- ceutically acceptable carrier.

[0015] In some embodiments, the compositions are administered intravenously. In other embodiments, the compositions are administered intranasally. In other embodiments, the compositions are administered orally.

[0016] In some embodiments, the 2-FDCK is administered in a unit dosage composition, hi some embodiments, the 2-FDCK is in a unit dosage form ranging from 1 mg to 1,000 mg.

[0017] In some embodiments, the method further comprises administering at least one antidepressant. In certain embodiments, the at least one antidepressant is selected from the group consisting of monoamine oxidase inhibitors, tricyclic compounds, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors; noradrenergic and specific serotonergic agents, and atypical antidepressants. In certain embodiments, the at least one antidepressant is selected from the group consisting of imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, clomipramine, fluoxetine, duloxetine, escitalopram, citalopram, sertraline, paroxetine, fluvoxamine, nefazadone, venlafaxine, milnacipran, reboxetine, lithium, mirtazapine, phenelzine, tranylcypromine, moclobemide, kava-kava, St. John's wort, S-adenosylmethionine, thyrotropin-releasing hormone, neurokinin receptor antagonists, and triiodothyronine. In further specific embodiments, the at least one antidepressant is selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, clomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, mirtazapine, and bupropion.

[0018] In some embodiments, 2-FDCK is self-administered or administered under professional supervision.

[0019] In some embodiments, a pharmaceutical composition for the treatment of treatment-refractory or treatment-resistant depression is provided, comprising 2-FDCK, optionally at least one antidepressant, and at least one pharma- ceutically acceptable carrier. [Brief description of the drawings]

[0020] (Not stated in the original text) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] Detailed Description definition The following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0022] As used herein, the terms “S-ketamine,” “S-ketamine hydrochloride,” and “esketamine” refer to the (S)-enantiomer of ketamine, also known as (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride, having the formula: [ka] "H" refers to the corresponding hydrochloride salt thereof,

[0023] As used herein, the terms “2-FDCK”, “fluoroketamine”, and “2-fluorodeschloroketamine” refer to 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one, also known as 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one, of the formula: [ka] The compound, represented by the formula: is an analogue of ketamine in which the chlorine group is replaced by fluorine.

[0024] As used herein, the term "antidepressant" refers to any drug that can be used to treat depression.Suitable examples include monoamine oxidase inhibitors such as phenelzine, tranylcypromine, moclobemide, tricyclics such as imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, clomipramine, amoxapine, tetracyclics such as maprotiline, acyclics such as nomifensine, triazolopyridines such as trazodone, serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, citalopram, citrapram, escitrapram, fluvoxamine, serotonin receptor antagonists such as nefazadone, venlafaxine, milnacipran, These include, but are not limited to, serotonin norepinephrine reuptake inhibitors such as desvenlafaxine, duloxetine; noradrenergic and certain serotonergic agents such as mirtazapine; norepinephrine reuptake inhibitors such as reboxetine, edivoxetine; atypical antidepressants such as bupropion; natural products such as lithium, kava-kava, St. John's wort; dietary supplements such as s-adenosylmethionine; and neuropeptides such as thyrotropin-releasing hormone; compounds that target neuropeptide receptors such as neurokinin receptor antagonists; and hormones such as triiodothyronine.

[0025] The term "chiral" refers to a molecule that has the property of being non-superimposable with its mirror image partner.

[0026] As used herein, the term "stereoisomers" means compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0027] The term "enantiomers" as used herein refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, and may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0028] Stereochemical definitions and rules used herein generally follow those of S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule about its chiral centers. The prefixes d and l, or (+) and (-), are used to specify the sign of rotation of plane polarized light by the compound, with (-) or l meaning that the compound is levorotatory; (+) or d is dextrorotatory.

[0029] A "racemic mixture" or "racemate" is an equimolar (or 50:50) mixture of two enantiomeric species, devoid of optical activity. A racemic mixture may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0030] Where a compound exists in various tautomeric forms, the invention is not limited to any one particular tautomer, but rather encompasses all tautomers.

[0031] The present disclosure includes compounds of Formula I with all possible isotopes of atoms present in the compound. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include tritium and deuterium. 11 C. 13 C, and 14 Contains C.

[0032] As used in this specification, including the claims, singular words such as "a," "an," and "the" also include the corresponding plural forms unless the context clearly dictates otherwise.

[0033] Whenever a range of numerical values ​​is given herein, it is meant to include any numerical values ​​(fractional or integer) recited within the given range. The phrases "ranging between" a first and second designation number and "ranging from" a first designation number to a second designation number are used interchangeably herein and are meant to include the first and second designation numbers and all fractional and integer numbers therebetween.

[0034] The dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such range is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a range disclosed as "10 mg" is intended to mean "about 10 mg."

[0035] The term "about," when used prior to a numerical designation of temperature, time, amount, concentration, and the like, indicates approximations, including ranges, which may vary, for example, by (+) or (-) 10%, 5%, 1%, or any subranges or subvalues ​​therebetween, depending on the nature of the parameter and measurement. In some embodiments, the term "about" used in reference to a dose means that the dose may vary by + / - 10%. When a range of values ​​is listed, it is intended to encompass each value and subrange within the range.

[0036] The terms "comprise," "comprising," "includes," "including," "having" and their conjugations mean "including but not limited to."

[0037] The term "consisting of" means "including and limited to."

[0038] Unless otherwise specified, the term "saline" refers to a 0.9% by weight aqueous solution of sodium chloride.

[0039] As used herein, the term "method" refers to ways, means, techniques, and procedures for accomplishing a particular task, including, but not limited to, known methods, means, techniques, and procedures or methods, means, techniques, and procedures that are readily developed by those skilled in the art of chemistry, pharmacology, biology, biochemistry, and medicine from known methods, means, techniques, and procedures.

[0040] The term "administration" or "administering" a subject compound means providing a compound of the invention, a pharma- ceutically acceptable salt, a pharma- ceutically acceptable solvate, or a solvate thereof, to a subject in need of treatment.

[0041] As used herein, the term "composition" or "pharmaceutical composition" refers to a mixture of at least one compound, such as 2-FDCK, or a pharma- ceutically acceptable salt thereof, with at least one, and optionally two or more, other pharma- ceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, excipients, and the like.

[0042] The term "effective amount" or "therapeutically effective amount" as used herein refers to a sufficient amount of 2-FDCK administered to relieve to some extent one or more symptoms of the disease or condition being treated. This may result in reduction and / or alleviation of the signs, symptoms, causes of the disease, or other desired changes in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition containing a compound disclosed herein that is required to provide a clinically significant reduction in disease symptoms. An appropriate "effective" amount in a particular case may be determined using techniques such as a dose escalation study.

[0043] When the present invention relates to a combination of drugs, the term "therapeutically effective amount" refers to the amount of the combination of drugs that are added together so that the combined effect elicits the desired biological or medical response. For example, a therapeutically effective amount of a combination therapy including 2-FDCK and a serotonin reuptake inhibitor would be an amount of 2-FDCK and an amount of a serotonin reuptake inhibitor that, when taken together or sequentially, have a therapeutically effective combined effect and may produce a synergistic effect. Furthermore, in the case of a combination therapy in a therapeutically effective amount, the amount of each component of the combination may or may not be therapeutically effective individually.

[0044] The optimal dose to be administered can be easily determined by those skilled in the art and varies depending on the specific compound(s) used, the method of administration, the strength of the formulation, and the progression of the disease state.Furthermore, the dosage may need to be adjusted depending on factors related to the specific patient being treated, such as the patient's sex, age, weight, diet, administration time, and concomitant diseases / drugs.

[0045] In one embodiment, 2-FDCK is administered at a dose ranging from about 0.01 mg to about 1000 mg, or any amount or range within that range, preferably about 0.01 mg to about 500 mg, or any amount or range within that range, preferably about 0.1 mg to about 250 mg, or any amount or range within that range. In another embodiment, 2-FDCK is administered at a dose ranging from about 0.01 mg to about 1000 mg, preferably selected from the group consisting of 0.01 mg, 0.025 mg, 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 500 mg.

[0046] As used herein, the term "pharmaceutical acceptable" refers to a material, such as a carrier or diluent, that does not abolish the biological activity or properties of the compounds described herein. Such a material may be administered to an individual without causing undesirable biological effects or adversely interacting with the components of the composition in which it is contained.

[0047] The term "carrier" as used herein refers to a compound or agent that promotes the uptake of 2-FDCK into cells or tissues. The term "pharmaceutically acceptable carrier" as used herein includes any solvent, dispersion medium, coating agent, surfactant, antioxidant, preservative (antibacterial agent, antifungal agent, etc.), isotonicity agent, absorption retardant, salt, preservative, drug stabilizer, binder, excipient, disintegrant, lubricant, sweetener, flavoring agent, dye, etc., and combinations thereof, as known to those skilled in the art (e.g., Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329; Remington: The Science and Practice of Pharmacy, 21 st (Ed. Pharmaceutical Press 2011; and subsequent versions). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.

[0048] The term "reduced" or "reducing" or "decreasing" as used herein generally refers to a statistically significant amount of reduction. However, for the avoidance of doubt, "reduced" refers to a reduction of at least 10% compared to a reference level as defined herein, for example, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, at least 95%, at least 99% or 100% reduction or less (i.e., substantially undetectable or below the level of detection), including reduction, or any reduction between 10-100% compared to a reference level.

[0049] As used herein, the term "standard" or "reference" can be a simple standard that defines a baseline for comparison, such as a healthy individual who is not depressed.

[0050] As used herein, the terms "treat", "treating", or "treatment" of any disease or disorder refer, in one embodiment, to ameliorating the disease or disorder (i.e., slowing, halting, or alleviating the progression of the disease or at least one of its clinical symptoms). In another embodiment, "treat", "treating", or "treatment" refers to alleviating or improving at least one physical parameter, including one that may not be discernible by the patient. In yet another embodiment, "treat", "treating", or "treatment" refers to modulating the disease or disorder physically (e.g., through stabilization of discernible symptoms), physiologically (e.g., through stabilization of physiological parameters), or both. In yet another embodiment, "treat", "treating", or "treatment" refers to preventing or slowing the onset, development, or progression of the disease or disorder.

[0051] As used herein, the term "subject" refers to a warm-blooded animal, such as a human, that will benefit biologically, medically, or in quality of life from the treatment. The subject may be a mammal or a non-mammal. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cows, horses, sheep, goats, pigs; rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish, and the like. In one embodiment, the subject is a human. It may be a human who has been diagnosed as needing treatment for a disease or disorder disclosed herein.

[0052] As used herein, a subject is "in need of" a treatment if the subject would benefit biologically, medically, or in quality of life from such treatment.

[0053] Depression and Treatment-Resistant Depression (TRD) As used herein, the term "depression" or "major depressive disorder (MDD)" is defined to include major depressive disorder, unipolar depression, treatment-resistant depression, resistant depression, anxious depression, bipolar depression, and dysthymia (also referred to as dysthymic disorder). Preferably, the depression is major depressive disorder, unipolar depression, treatment-resistant depression, resistant depression, anxious depression, or bipolar depression.

[0054] Depression can be characterized by sadness, loss of interest in activities, and low energy. Other symptoms include loss of confidence and self-esteem, inappropriate feelings of guilt, thoughts of death or suicide, poor concentration, and disturbances in sleep and appetite. A variety of physical symptoms may also be present. Depressed moods are common, especially after experiencing setbacks in life, but a depressive disorder is only diagnosed when symptoms reach a threshold and last for at least two weeks. Depression varies in severity from mild to very severe and includes unipolar and bipolar depression, as well as seasonal affective disorder (SAD). Depression is also typically characterized by eight cardinal dimensions to define the profile of depression in children and adolescents: pessimism, poor concentration, sleep disturbance, anhedonia, fatigue, loneliness, low self-esteem, and somatic complaints. Depression can occur as an idiopathic disorder (without associated physical illness) or it can be a psychiatric symptom of a physical illness, especially many neurodegenerative disorders.

[0055] Scales known in the art to be applied in assessing levels of depression include: (1) Hamilton Depression Rating Scale 28-Item: primary outcome measure (Hamilton MJ, Neurol Neurosurg Psychiatry 1960; 23:56-62; Hamilton M., Br J Social Clin Psychology 1967; 6:278-296). (2) Columbia-Suicide Severity Rating Scale (Posner K. et al., Am J Psychiatry. 2011; 168(12): 1266-77). (3) Clinical Global Improvement Scale-Severity and Improvement (Guy W. Clinical Global Impression (CGI) ECDEU Assessment manual for Psychopharmacology. Rockville, Md.: US Dept Health Education and Welfare 1976). (4) Quick Inventory of Depressive Symptoms, Self-Report version (Trivedi MH et al., Psychol Med. 2004; 34(1):73-82). (5) Concise Health Risk Tracking (Trivedi MH et al., J Clin Psychiatry. 2011; 72(6):757-64). (6) MGH Cognitive and Physical Functioning Questionnaire (Fava M. et al., Psychother Psychosom. 2009; 78(2):91-7). (7) Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott J. et al., Psychopharmacol Bull. 1993; 29(2):321-6). (8) Brief Psychiatric Rating Scale (Andersen J. et al. Psychopathology. 1989; 22(2-3):168-76; Hafkenscheid A., Acta Psychiatr Scand. 1991; 84(3):294-300). (9) At baseline and at the end of Phase 3 only - neurocognitive test battery: immediate and delayed verbal recall, speed of comprehension, forward and backward digit span, N-back test, and trail making task (Trandafir A. et al., Schizophr Res. 2006; 81(2-3):217-26).

[0056] As used herein, the term "treatment-refractory or treatment-resistant depression" and the abbreviation "TRD" are intended to be defined as major depressive disorder that has not responded to adequate dosing of at least two antidepressants, preferably two or more antidepressants, and more preferably two to three antidepressants.

[0057] Those skilled in the art will recognize that failure to respond to appropriate administration of a given antidepressant can be determined retrospectively or prospectively.In one embodiment, at least one of the failures to respond to appropriate antidepressant administration is determined prospectively.In another embodiment, at least two of the failures to respond to appropriate antidepressant administration are determined prospectively.In another embodiment, at least one of the failures to respond to appropriate antidepressant administration is determined retrospectively.In another embodiment, at least two of the failures to respond to appropriate antidepressant administration are determined retrospectively.

[0058] Without intending to be bound by any particular theory, the inventors have observed that the dose-response curve of 2-FDCK is flatter than that of ketamine when administered in the same manner (see Figure 1). The difference in dose-response is large enough for use in the treatment of depression and can be used in a manner that eliminates many of the drawbacks (e.g., adverse side effects) inherent in the current practice of using ketamine to treat the same condition. Because the risk of developing debilitating side effects is reduced, several benefits may result from the use of 2-FDCK for TRD, including reduced time required for clinic visits, the possibility that patients may eventually be able to self-administer (further reducing costs), and / or the potential approval of 2-FDCK for over-the-counter sales. In contrast, as shown in Figure 2, other arylcyclohexamines such as 2-DCK and OPCE have dose-response curves that begin to rise sharply at low doses, making them less suitable as alternative treatments to ketamine.

[0059] Pharmaceutical Compositions and Combinations Pharmaceutical compositions of the present disclosure include at least 2-FDCK together with one or more pharma- ceutically acceptable carriers.

[0060] Those skilled in the art will recognize that both in vivo and in vitro tests using appropriate, known and generally accepted cellular and / or animal models can predict the ability of a test compound to treat or prevent a given disease.

[0061] When the present invention concerns the administration of a combination, the compounds may be administered simultaneously, sequentially, separately, or co-administered in a single pharmaceutical composition. When the compounds are administered separately, the number of administrations of each compound given per day does not necessarily have to be the same, for example, if one compound has a long or short duration of activity, the administration frequency will be less. Furthermore, the compounds may be administered simultaneously in divided or single combination form, at the same or different time points during the treatment period, via the same or different routes of administration. Thus, the present invention is to be understood as embracing all dosing regimes of simultaneous or alternating treatment, and the term "administration" should be interpreted accordingly.

[0062] As used herein, the terms "co-therapy", "combination therapy", "adjunctive treatment", "adjunctive therapy" and "combined treatment" refer to the treatment of a patient in need thereof by administering 2-FDCK in combination with one or more agents, and optionally in combination with one or more atypical antipsychotics, where the antidepressant, esketamine and the antidepressant are administered by any suitable means, simultaneously, sequentially, separately, or as a single pharmaceutical formulation. When 2-FDCK and the antidepressant are administered in separate dosage forms, the daily dosage of each compound may be the same or different. 2-FDCK and the antidepressant may be administered by the same or different routes of administration. Examples of suitable administration methods include, but are not limited to, oral, intravenous (iv), intranasal (in), intramuscular (im), subcutaneous (sc), transdermal, and rectal. The compounds may also be administered directly to the nervous system by routes including, but not limited to, intracerebral, intraventricular, intracerebroventricular, intrathecal, intrathoracic, intraspinal and / or paraspinal routes of administration, by delivery via intracranial or intraspinal needles and / or catheters, with or without a pump device. 2-FDCK and antidepressants may be administered simultaneously, in divided or single forms, at the same or different times during the treatment period, according to simultaneous or alternating dosing schedules.

[0063] Pharmaceutical compositions containing one or more of the compounds of the present invention described herein as active ingredients can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the desired route of administration (oral, parenteral, etc.). Thus, for liquid oral preparations such as suspensions, elixirs, and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavorings, preservatives, stabilizers, coloring agents, etc.; for solid oral preparations such as powders, capsules, tablets, etc., suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. The solid oral preparations may be coated with substances such as sugars to regulate the primary site of absorption, or may be enteric coated. For parenteral administration, the carrier is usually composed of sterile water, and other ingredients may be added to enhance solubility or preservation. Injectable suspensions or solutions can also be prepared utilizing aqueous carriers with suitable additives.

[0064] To prepare the pharmaceutical composition of the present invention, 2-FDCK as an active ingredient, and optionally at least one antidepressant, are intimately mixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which may take a variety of forms depending on the form of preparation desired for administration, such as oral or parenteral, such as intramuscular. When preparing the composition in oral dosage form, any of the usual pharmaceutical media can be used. Thus, for example, for liquid oral preparations, such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavorings, preservatives, coloring agents, and the like; for solid oral preparations, such as powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like. Because of ease of administration, tablets and capsules are the most advantageous oral dosage unit forms, in which case it is clear that solid pharmaceutical carriers are used. If necessary, tablets may be sugar-coated or enteric-coated by standard techniques. For parenteral administration, the carrier will usually consist of sterile water, although other ingredients may be included for purposes such as facilitating solubility or preservation. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be used. The pharmaceutical compositions herein will contain the amount of active ingredient required to deliver the effective dose described above per dosage unit (e.g., tablet, capsule, powder, injection, teaspoon, and the like). The pharmaceutical compositions herein may contain, per dosage unit (e.g., tablet, capsule, powder, injection, teaspoon, etc.), about 0.01 mg to about 1000 mg, or any amount or range therein, and may be administered at a dose of each active ingredient of about 0.01 mg / kg to about 1.5 mg / kg, or any amount or range therein, preferably about 0.01 mg / kg / day to about 0.75 mg / kg, or any amount or range therein, preferably about 0.05 mg / kg to about 0.5 mg / kg, or any amount or range therein, preferably about 0.1 mg / kg to about 0.5 mg / kg, or any amount or range therein. However, dosages may vary depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used.Either daily or periodic dosing can be used.

[0065] Preferably, these compositions are in unit dosage form such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosols or liquid sprays, drops, ampoules, automatic injection devices or suppositories; or by oral, parenteral, intranasal, sublingual or rectal administration, or by inhalation or insufflation. Alternatively, the compositions may be provided in a form suitable for weekly or monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For the preparation of solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical carrier, such as cornstarch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gum, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a homogeneous mixture of the compound of the present invention or a pharma-ceutically acceptable salt thereof. When these preformulation compositions are referred to as homogenous, it means that the active ingredients are uniformly dispersed throughout the composition such that the composition may be readily further divided into equally effective dosage forms such as tablets, pills, and capsules. This solid preformulation composition is then further divided into unit dosage forms of the type described above containing from about 0.01 mg to about 1,000 mg of each active ingredient, or any amount or range therein. The tablets or pills of the novel compositions may be coated or otherwise compounded to provide a dosage form affording the advantage of sustained action. For example, the tablet or pill may comprise an inner dosage component and an outer dosage component, the latter being an envelope covering the former. The two components may be separated by an enteric layer which resists disintegration in the stomach and permits the inner component to pass intact into the duodenum or be delayed in release. A variety of materials may be used for such enteric layers or coatings, including a number of polymeric acids, including such materials as shellac, cetyl alcohol, and cellulose acetate.

[0066] Liquid forms in which the novel compositions of the present invention can be formulated for oral or injectable administration include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions including edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, or gelatin.

[0067] The method of treating refractory or treatment-resistant depression described in the present invention can also be carried out using a pharmaceutical composition comprising any of the compounds defined herein and a pharma- ceutically acceptable carrier. The pharmaceutical composition can contain between about 0.01 mg and about 1000 mg of the compound, or any amount or range therein; preferably about 0.05 mg to about 500 mg of the compound, or any amount or range therein of each active ingredient, and can be configured into any form suitable for the selected mode of administration. Carriers include necessary and inert pharmaceutical excipients, including but not limited to binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solids such as pills, tablets, caplets, capsules (including immediate release, sustained release, and extended release formulations, respectively), granules, and powders, and liquids such as solutions, syrups, elixirs, emulsions, and suspensions. Dosage forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.

[0068] Advantageously, the compound of the present invention can be administered in a single dose per day, or the total daily dose can be divided into two, three or four doses per day.Furthermore, the compound of the present invention can be administered in intranasal form through topical use of suitable intranasal vehicles, or through transdermal skin patches well known to those skilled in the art.Because it is administered in the form of a transdermal delivery system, the dosage administration will naturally be continuous, not intermittent, throughout the entire dosage regimen.

[0069] For example, when orally administered in the form of tablet or capsule, the active drug ingredient can be combined with an oral non-toxic pharma- ceutically acceptable inert carrier such as ethanol, glycerol, water, etc. In addition, suitable binders, lubricants, disintegrants and colorants can be incorporated into the mixture as desired or necessary. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, etc.

[0070] The liquids are formed in suitably flavored suspending or dispersing agents, for example, the synthetic and natural gums, such as tragacanth, acacia, methylcellulose, and the like. For parenteral administration, sterile suspensions and solutions are desired. When intravenous administration is required, isotonic preparations, which generally contain suitable preservatives, are used.

[0071] To prepare the pharmaceutical composition of the present invention, esketamine, optionally in combination with at least one antidepressant, is intimately mixed as an active ingredient with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which may take a wide variety of forms depending on the form of preparation desired for administration (such as oral or parenteral). Suitable pharmaceutically acceptable carriers are well known in the art. A description of some of these pharmaceutically acceptable carriers can be found in the "Handbook of Pharmaceutical Excipients" published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

[0072] Methods for formulating pharmaceutical compositions are described in Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc. and many other publications.

[0073] In one embodiment of the present invention, a method of treating treatment-refractory or treatment-resistant depression is provided, comprising administering to a subject in need thereof a therapeutically effective amount of 2-fluorodichloroketamine (2-FDCK).

[0074] In some embodiments, 2-FDCK is administered in an amount of about 0.01 mg / kg to about 1.5 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.1 mg / kg to about 0.5 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.1 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.15 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.2 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.25 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.3 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.35 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.4 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.45 mg / kg. In some embodiments, 2-FDCK is administered in an amount of about 0.5 mg / kg.

[0075] In some embodiments, 2-FDCK is administered in the range of about 0.01 mg to about 1000 mg. In some embodiments, 2-FDCK is administered in the range of about 5 mg to about 100 mg. In some embodiments, 2-FDCK is administered in an amount of about 5 mg. In some embodiments, 2-FDCK is administered in an amount of about 10 mg. In some embodiments, 2-FDCK is administered in an amount of about 15 mg. In some embodiments, 2-FDCK is administered in an amount of about 20 mg. In some embodiments, 2-FDCK is administered in an amount of about 25 mg. In some embodiments, 2-FDCK is administered in an amount of about 30 mg. In some embodiments, 2-FDCK is administered in an amount of about 35 mg. In some embodiments, 2-FDCK is administered in an amount of about 40 mg. In some embodiments, 2-FDCK is administered in an amount of about 45 mg. In some embodiments, 2-FDCK is administered in an amount of about 50 mg. In some embodiments, 2-FDCK is administered in an amount of about 55 mg. In some embodiments, 2-FDCK is administered in an amount of about 60 mg. In some embodiments, 2-FDCK is administered in an amount of about 65 mg. In some embodiments, 2-FDCK is administered in an amount of about 70 mg. In some embodiments, 2-FDCK is administered in an amount of about 75 mg. In some embodiments, 2-FDCK is administered in an amount of about 80 mg. In some embodiments, 2-FDCK is administered in an amount of about 85 mg. In some embodiments, 2-FDCK is administered in an amount of about 90 mg. In some embodiments, 2-FDCK is administered in an amount of about 95 mg. In some embodiments, 2-FDCK is administered in an amount of about 100 mg.

[0076] In some embodiments, 2-FDCK forms part of a composition further comprising a pharma- ceutically acceptable carrier. In one embodiment, the composition is administered intravenously. In one embodiment, the composition is administered intranasally. In one embodiment, the composition is administered orally.

[0077] In some embodiments, 2-FDCK is administered in a unit dosage form composition. In further embodiments, 2-FDCK is in a unit dosage form ranging from XX mg to YY mg. In some embodiments, 2-FDCK is in a unit dosage form ranging from XX mg. In some embodiments, 2-FDCK is in a unit dosage form ranging from QQ mg. In some embodiments, 2-FDCK is in a unit dosage form ranging from WW mg. In some embodiments, 2-FDCK is in a unit dosage form ranging from YY mg.

[0078] In another aspect of the present disclosure, the method further comprises administering at least one antidepressant.In some embodiments, the at least one antidepressant includes, but is not limited to, monoamine oxidase inhibitors, tricyclic drugs, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors; noradrenergic and specific serotonergic drugs and atypical antidepressants. In some embodiments, the at least one antidepressant includes, but is not limited to, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, clomipramine, fluoxetine, duloxetine, escitalopram, citalopram, sertraline, paroxetine, fluvoxamine, nefazadone, venlafaxine, milnacipran, reboxetine, lithium, mirtazapine, phenelzine, tranylcypromine, moclobemide, kava-kava, St. John's wort, S-adenosylmethionine, thyrotropin-releasing hormone, neurokinin receptor antagonists, and triiodothyronine. In some embodiments, the at least one antidepressant includes, but is not limited to, phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, clomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, mirtazapine, and bupropion.

[0079] In another aspect of the present disclosure, provided herein is a pharmaceutical composition for the treatment of treatment-refractory or treatment-resistant depression comprising 2-FDCK, optionally at least one antidepressant, and at least one pharma- ceutically acceptable carrier.

[0080] The examples and preparations provided below further describe and illustrate the compounds disclosed herein and methods for preparing such compounds. It should be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples and preparations.

[0081] Various embodiments and aspects of the present invention as delineated above and as claimed below are found experimentally supported in the following examples. EXAMPLES

[0082] The examples and preparations provided below further describe and illustrate the compounds disclosed herein and methods for preparing such compounds. It should be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples and preparations.

[0083] Example 1: 2-FDCK exhibits antidepressant effects in the mouse forced swimming test overview Male 10-week-old C57BL / 6N mice (Taconic) are acclimated to the vivarium 1 week prior to testing. A 2-day FST paradigm is employed in which mice are exposed to a 10-min test in the absence of drug, followed the next day by a 6-min test in the presence of drug. 2-FDCK is administered intraperitoneally (i.p.) in saline vehicle 30 min prior to the FST. All animals are drug-naïve and have not previously undergone behavioral testing.

[0084] material and method animal Ten-week-old male C57BL6N / Tac mice were housed four mice per cage under a 12:12 h light / dark cycle and allowed to acclimate for approximately 1 week before behavioral procedures. Food and water were provided ad libitum. All procedures were in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals.

[0085] Drug treatment 2-FDCK is dissolved in saline vehicle (0.9% sodium chloride). In 2-FDCK dose-response experiments, mice are administered vehicle or various doses of 2-FDCK intraperitoneally 30 min before behavioral testing.

[0086] Behavioral Procedures Mice are tested in a forced swim test (FST) procedure over a 2-day period. On day 1, all mice received a mock intraperitoneal (ip) vehicle injection to familiarize them with the injection procedure, and 30 min later, they were placed in one of five identical cylindrical chambers (24 cm × 15 cm) half-filled with warm water (26 cm × 15 cm) at (26) ± 2 °C for 10 min without data collection. On day 2, mice were placed in the cylinder for a 6 min session after receiving an i.p. injection 30 min earlier, and the immobility time was recorded during the last 4 min. Mice that received 2-FDCK showed shorter immobility times compared to mice that received vehicle only.

[0087] Example 2: Dose-response curves of selected arylcyclohexamines For safety reasons - when exploring new psychotropic drugs - logarithmic scales are employed for initial dosing to figure out whether the compound is active and, if so, at what dose range.

[0088] After this initial experiment with OPCE, 2-DCK, and 2-FDCK (ketamine was later added to the study for reference), it was clear that the corresponding doses of 3mg, 15mg, and 30mg were effective as lower thresholds for further exploration. To explore the psychiatric effects of higher doses, it was decided to double, triple, and quadruple the lower threshold dose. Every few days, a portion of one of the compounds was weighed out on an Ohaus Scout balance and prepared for administration via nasal spray using a refillable nasal spray bottle.

[0089] The Shulgin "+" based rating system for psychedelic experiences (SHULGIN, AT, & SHULGIN, A. (1991). Pihkal: a chemical love story. Berkeley, CA, Transform Press, page 964) was chosen for a year-long investigation of a range of these arylcyclohexamines. Although the molecular families and types of experiences targeted differed from those originally designed for the rating system, the simplicity of the scale makes it particularly well suited to this type of exploration for several reasons: (1) The experiences produced by a new psychedelic drug are often indescribable. A language for discussing new states of consciousness must be developed and agreed upon, and this process occurs naturally after many people have experienced the compound and developed a discussion of its effects. (2) Arylcyclohexamines often inhibit or alter movement in ways that make writing difficult or impossible during the experience. (3) The dissociative nature of many arylcyclohexamine effects does not allow for long time frames for the focusing involved in complex or detailed determinations.

[0090] It was therefore thought preferable to use simple +, ++, +++, ++++ 1, 2, 3, 4 to assess the intensity of the experience without seeking an objective measure of intensity.

[0091] The data collected from this study is summarized in the following table: Table 1 [Table 1] [Table 2] [Table 3] [Table 4]

[0092] If the doses are scaled to units that allow all dose / response curves to fit on the same graph, running a spline through the data points will yield curves qualitatively similar to the curve displayed in Figure 2.

[0093] While the present invention has been described in connection with specific embodiments thereof, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the appended claims. Those skilled in the art will readily appreciate that the specific methods and results discussed in the examples are merely illustrative of the invention, as more fully described in the claims.

[0094] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference. Furthermore, citation or identification of a reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent section headings are used, they should not be construed as necessarily limiting.

Claims

1. 1. A pharmaceutical composition for treating depression, comprising a therapeutically effective amount of 2-fluorodichloroketamine (2-FDCK) and at least one pharmaceutically acceptable carrier, wherein the depression is optionally treatment-refractory or treatment-resistant depression.

2. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.01 mg / kg to 1.5 mg / kg of 2-FDCK.

3. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.2 mg / kg to 0.5 mg / kg of 2-FDCK.

4. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 0.01 mg to 1000 mg of 2-FDCK.

5. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 1 mg to 100 mg of 2-FDCK.

6. 10. The pharmaceutical composition of claim 1, wherein the composition is formulated for intravenous administration.

7. 10. The pharmaceutical composition of claim 1, wherein the composition is formulated for intranasal administration.

8. 10. The pharmaceutical composition of claim 1, wherein the composition is formulated for oral administration.

9. 10. The pharmaceutical composition of claim 1, further comprising at least one antidepressant.

10. 10. The pharmaceutical composition of claim 9, wherein the at least one antidepressant is selected from the group consisting of monoamine oxidase inhibitors, tricyclic compounds, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors, noradrenergic and specific serotonergic agents, and atypical antidepressants.

11. 10. The pharmaceutical composition of claim 9, wherein the at least one antidepressant is selected from the group consisting of imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, clomipramine, fluoxetine, duloxetine, escitalopram, citalopram, sertraline, paroxetine, fluvoxamine, nefazadone, venlafaxine, milnacipran, reboxetine, lithium, mirtazapine, phenelzine, tranylcypromine, moclobemide, kava-kava, St. John's wort, S-adenosylmethionine, thyrotropin-releasing hormone, neurokinin receptor antagonists, and triiodothyronine.

12. 10. The pharmaceutical composition of claim 9, wherein the at least one antidepressant is selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, clomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, mirtazapine, and bupropion.

Images